In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
COVID-19 and Cardiology Read more

Cardiovascular disease is biggest killer globally but cancer overtakes in some countries

PURE results on causes of death presented in a Hot Line Session today at ESC Congress 2019 together with WCC

Risk Factors and Prevention


Paris, France – 3 Sept 2019: Cardiovascular disease remains the main cause of death globally, but cancer has overtaken it to become the leading cause of death in some high-income and upper-middle-income countries.  The late breaking results from the PURE study are presented in a Hot Line Session today at ESC Congress 2019 together with the World Congress of Cardiology(1).

Co-primary author Dr Darryl Leong of the Population Health Research Institute, McMaster University, Hamilton, Canada said: “If the pattern of declining cardiovascular deaths seen in the last few decades in high-income countries continues and the same pattern is followed by some middle- and low-income countries, then it is possible that cancer will become the most common cause of death worldwide in a few decades. The high cardiovascular mortality seen in the PURE study in middle- and low-income countries is likely related to low access to effective healthcare.”

Patterns of disease and death across the world are shifting as communicable disease rates fall in low-income countries and prevention and treatments for cardiovascular disease improve in high-income countries. Developing effective strategies to improve global health requires a contemporary understanding of these trends. Substantial further reductions in cardiovascular disease are possible by wider adoption of proven prevention strategies and treatments in all countries.

“Existing data are limited because they were typically collected from one country or countries within a single or a few regions, making our ability to compare regions at different economic levels potentially unreliable,” said Dr Leong. “Also, advances in the prevention and treatment of cardiovascular disease that have impacted populations were not captured in data collected more than 15 to 20 years ago.”


The PURE study(2) was conducted in 21 countries (4 high-income [HIC], 12 middle-income [MIC], and 5-low-income [LIC]) and included urban and rural sites across five continents. Households were selected to broadly represent the sociodemographic composition of their community. This analysis included 162,534 community-dwelling adults aged 35 to 70 years. Participants were contacted at least every three years to ascertain their vital status and the occurrence of incident diseases and hospitalisations. Participants were followed for nearly ten years.

Overall mortality was highest in LIC, intermediate in MIC, and lowest in HIC. This pattern was observed for all common causes of death except cancer where the mortality rates in LIC, MIC, and HIC were similar.

Cardiovascular disease was the most common cause of death overall. But in HIC, cancer deaths occurred twice as often as cardiovascular deaths. In contrast, in LIC, cardiovascular deaths were three times more frequent than cancer deaths, with MIC being in between HIC and LIC. Put another way, the ratio of cardiovascular deaths to cancer deaths was 0.4 in HIC, 1.3 in MIC, and 3.0 in LIC.

“This epidemiologic transition may be partly due to improved strategies to prevent and treat cardiovascular disease in high-income countries,” said co-primary author Dr Gilles Dagenais of the Quebec Heart and Lung Institute, Canada. “Alongside this, apart from tobacco control, effective strategies to prevent and treat cancer have yet to yield large reductions in the incidence of most cancers or deaths from common cancers as it was documented for cardiovascular disease. While very recent advances in cancer treatment will be expected to ultimately deliver impactful improvements in cancer survival, this will require improved access and wider use of such treatments.”

Participants in HIC with cardiovascular disease were less likely to die from their disease compared to MIC and LIC. This paralleled the higher rates of medication use and hospitalisation for cardiovascular disease in HIC.

Professor Salim Yusuf, senior author of the study and Principal Investigator of PURE2, said: “The high rates of cardiovascular disease and related mortality in low-income countries are likely related to gaps in access to, or availability of, healthcare. This was shown by the lower use of preventive medications and less frequent hospitalisation for cardiovascular disease. Improving access to quality healthcare is key to reducing deaths from cardiovascular and other diseases in low- and middle-income countries.”

He concluded: “As cardiovascular disease declines in many countries, cancer mortality is likely to become the leading cause of death in the future.”

ENDS

Notes to editor

Notes to editors

Authors: ESC Press Office 
Mobile: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2019 together with the World Congress of Cardiology is #ESCCongress

Funding: The PURE study was funded from multiple (approximately 70) sources, including the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, several pharmaceutical companies, the Population Health Research Institute and Funding Agencies in several participating countries.

Disclosures: None to declare.

References and notes

(1) PURE: Contrasting patterns of cardiovascular disease, cancers and related mortality between high- versus low-middle income countries will be discussed during:

(2) PURE: The Prospective Urban Rural Epidemiologic Study was initiated in 2002 and is now established in 27 countries and has enrolled over 200,000 participants from the general population from 997 urban and rural communities in five continents. It is studying the environmental, societal, behavioural and genetic causes of CVD and other non communicable diseases and how healthcare and health systems modify the incidence and deaths from several diseases. 

About ESC Congress

ESC Congress is the world’s largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2019 together with the World Congress of Cardiology takes place from 31 August to 4 September at the Expo Porte de Versailles in Paris, France. Explore the scientific programme.

About the European Society of Cardiology 

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2019 together with the World Congress of Cardiology. It does not necessarily reflect the opinion of the European Society of Cardiology.